Study Title
Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Study Details
Description:
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
Sponsor:
Bivision Pharmaceuticals, Inc.
Contacts:
Bivision Pharmaceuticals, Inc.bivision.public1@bivisionpharma.com
86-21-50886996
Government Study Link:
NCT06139575 - Click here to see study onClinicalTrials.gov